News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2018

Epigenomics AG Announces Initiation of a Prospective Clinical Study for Liver Cancer Detection

PDF Berlin (Germany) and San Diego, CA (U.S.A.), 20 December, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced the initiation of a multi-center validation and development study of its methylated cell free DNA biomarkers to aid in the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis. As an expansion of its molecular […]

Read more

Centers for Medicare & Medicaid Services issue official 2019 Clinical Lab Fee Schedule including Epi proColon®

PDF Berlin (Germany) and San Diego, CA (U.S.A.), December 19, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced that the Centers for Medicare & Medicaid Services (CMS) have issued its official 2019 Clinical Lab Fee Schedule (CLFS) on December 14, 2018, including the final reimbursement rate of $192 for Epi proColon®, […]

Read more

Epigenomics AG Announces 2018 Third Quarter and Nine Months Financial Results

PDF Berlin (Germany) and San Diego, CA (U.S.A.), November 7, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced its financial results for the third quarter and the nine months 2018 ending September 30. Recent operational highlights -In September 2018, U.S. Congress urged the Centers of Medicare & Medicaid Services (CMS) to […]

Read more

Epigenomics AG Announces Veterans Administration’s Adherence Study using Epi proColon® Colorectal Cancer Screening Blood Test

PDF Berlin (Germany) and San Diego, CA (U.S.A.), October 31, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced the Veterans Administration – New York Harbor Healthcare System (VA-Manhattan) is commencing a study to assess the adherence impact of offering a blood-based colorectal cancer screening test and colonoscopy completion in patients who have refused […]

Read more

Epigenomics AG obtains CE Mark for Liquid Biopsy Test for Liver Cancer Detection

PDF – CE Mark for liver cancer blood test enables commercialization in Europe – Prospective U.S. trial for FDA submission to be initiated in 2019 – Investigating optimal path for CFDA approval in China Berlin (Germany) and San Diego, CA (U.S.A.), October 29, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced that it […]

Read more

Epigenomics AG successfully completes capital increase; gross proceeds of EUR 22.3 million

PDF Publication of Inside Information according to Article 17 MAR Berlin, October 23, 2018 – Epigenomics AG (FSE: ECX; OTCQX: EPGNY) (“Company”) has fully placed the new shares from the capital increase resolved on October 7, 2018 of up to EUR 12,007,180 (corresponds to 50% of the existing share capital). Accordingly, the Company’s share capital […]

Read more